Clinical Trials Logo

Schizophrenia Spectrum Disorders clinical trials

View clinical trials related to Schizophrenia Spectrum Disorders.

Filter by:

NCT ID: NCT06138054 Recruiting - Homelessness Clinical Trials

MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This study aims to test the feasibility and acceptability of a brief behavioral intervention that combines two treatments, Motivational Interviewing (MI) and Cognitive Behavioral Therapy (CBT), that have been shown to work in prior research studies. The format of the intervention will be a combination of in-person sessions and remote elements delivered via mobile phone (together called MI-CBTech). The goal of the intervention is to improve community integration in Veterans with serious mental illness (SMI) who have experienced homelessness. A time- and format-matched control arm will include remote mindfulness training. 50 Veterans with SMI experiencing homelessness will be randomized to one of the two arms (25 per arm).

NCT ID: NCT06136390 Recruiting - Clinical trials for Schizophrenia Spectrum Disorders

OXYMIND: Oxytocin-augmented Group Psychotherapy for Patients With Schizophrenia

OXYMIND
Start date: September 30, 2023
Phase: N/A
Study type: Interventional

The effectiveness of current treatment options for sociocognitive deficits and negative symptoms (NS) in schizophrenia spectrum disorders (SSD) remains limited. The cause of NS is thought to be an interference between the mesocorticolimbic dopamine system for social reward expectancy and the network for socioemotional processes. Oxytocin (OXT) may enhance functional connectivity between these neuronal networks. Lower plasma OXT levels correlate negatively with NS severity and deficits in social cognition in SSD. It has been shown that intranasal OXT administration improves social cognition in healthy subjects but in SSD results are inconsistent. According to the social salience hypothesis, the effect of OXT varies depending on the social context and individual factors. Also, OXT-mediated effects on psychopathology and NS may depend on genetic variants of OXT receptors (OXTR). In a pilot study, the investigators demonstrated a lower NS by OXT administration in the positive social context of MBGT in SSD. The investigators also demonstrated that NS and other symptoms improved after mindfulness-based group psychotherapy (MBGT). The aim of this study in individuals with SSD is to examine the effect of combining OXT administration with MBGT on NS, affect, and stress with psychological and biological markers. The main hypothesis to be tested is that the use of OXT compared to placebo prior to MBGT in patients with SSD will result in a greater reduction in NS. The research design is based on an experimental, triple-blind, randomized, placebo-controlled trial.

NCT ID: NCT05945602 Recruiting - Clinical trials for Schizophrenia Spectrum Disorders

Neurophysiologic Biomarkers for Cognitive Rehabilitation

Start date: October 1, 2023
Phase:
Study type: Observational

Cognitive symptoms of schizophrenia interfere with daily life-from managing self-care, to more complex tasks like taking medications and living independently. Unfortunately, these cognitive symptoms are not corrected by 'standard of care' treatments (antipsychotic medications), although some schizophrenia patients may experience modest clinical and cognitive benefits from cognitive remediation. To enhance the clinical impact of cognitive remediation and other rehabilitative interventions for Veterans living with chronic psychosis, this study will develop novel brain-based tools to help identify those Veterans who are most likely to benefit from pro-cognitive therapies. These studies may advance predictive algorithms that improve functional outcomes and life quality in Veterans with schizophrenia.

NCT ID: NCT05784948 Completed - Schizophrenia Clinical Trials

Safety and Efficacy of Virtual Reality Mindfulness in Patients With Psychosis

Start date: April 8, 2020
Phase: N/A
Study type: Interventional

This study is to evaluate the safety and efficacy of Virtual Reality Mindfulness in Patients With Psychosis.

NCT ID: NCT05333003 Recruiting - Clinical trials for Schizophrenia Spectrum Disorders

Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity

Sema
Start date: May 25, 2022
Phase: N/A
Study type: Interventional

Rates of obesity in patients with schizophrenia-spectrum disorder (SSD)s have reached epidemic proportions, with established contributing effects of antipsychotic (AP) medications. Among agents approved for chronic weight management, glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with reductions in cardiovascular mortality, with recent FDA approval for once weekly semaglutide for this indication. This study will investigate whether semaglutide is effective in reducing body weight in overweight or obese individuals with SSDs who are on APs and do not demonstrate adequate weight loss on metformin (the first line treatment for weight loss in SSDs).

NCT ID: NCT05247151 Completed - Clinical trials for Schizophrenia Spectrum Disorders

The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin

OXY
Start date: August 2, 2021
Phase: N/A
Study type: Interventional

In previous studies the neuropeptide oxytocin has been in particular associated with social enhancing and anxiety relieving effects. The purpose of this study is to investigate the effect of oxytocin on empathy in patients with schizophrenia. On a neurobiological level, social effects mediated by oxytocin are based on oxytocin's influence on the complexly regulated mesocorticolimbic dopamine system. Preliminary studies have already shown that oxytocin increases neuronal connections between social reward expectancy networks and networks for socioemotional processes in the brain, which on a behavioral level leads to increased social activation, motivation, and also improved social perception. Furthermore, an increase in empathy modulated by the amygdala has been shown in healthy individuals following oxytocin administration. In particular, primary psychotic disorders, such as schizophrenia, are associated with deficits in the domain of social cognition, including empathy, with the degree of negative symptoms playing an important mediating role. Another study demonstrated a significantly lower expression of empathy as well as a significantly lower oxytocin level in patients with schizophrenia compared to healthy subjects. According to the hypothesis of social salience, which describes an increased importance of certain social stimuli, the effect of oxytocin varies depending on specific contexts and individual variables of the perceiving person, such as the degree of negative symptoms. Therefore, based on such preliminary findings, the research project will explore an effect of oxytocin on empathy within a positively experienced and controlled context, especially in patients with schizophrenia regarding their negative symptoms.

NCT ID: NCT04799717 Completed - Psychotic Disorders Clinical Trials

Game-based Telehealth Therapeutic Intervention in First Onset Psychosis

Start date: August 31, 2021
Phase:
Study type: Observational

The goal is to provide combination of 2 hours of weekly game based telehealth therapeutic intervention along with CBT-P for children identified with first onset psychosis or to be clinically high risk for psychosis thus widening therapeutic services offered. Target outcome measures are improvement in clinical symptoms, treatment engagement, and reduced hospitalization rates.

NCT ID: NCT04230590 Active, not recruiting - Clinical trials for Schizophrenia Spectrum Disorders

Health Outcomes Via Positive Engagement in Schizophrenia

HOPE-S
Start date: November 4, 2019
Phase:
Study type: Observational

This is an observational study where digital, clinical and health utilization data are collected from individuals with schizophrenia spectrum disorders who have been recently discharged from a psychiatric hospitalization. The data will be used towards building a model/algorithm capable of monitoring mental health and predicting adverse clinical events, such as relapse and re-admissions.

NCT ID: NCT03883360 Withdrawn - Cannabis Use Clinical Trials

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

Start date: January 2050
Phase: Phase 2
Study type: Interventional

A large proportion of people with a schizophrenia-spectrum disorder, especially in the early stages of the disease, regularly consume cannabis. Cannabis use is associated with poor prognostic outcome; however, there are no effective interventions targeted at reducing cannabis use or its deleterious effects in this population. The present trial is designed to test whether cannabidiol (CBD), a cannabinoid whose effects are in many ways antagonistic to those of Δ9-tetrahydrocannabinol (THC), can reduce psychiatric symptoms, cognitive deficits, and cannabis use in people with recent-onset psychosis who regularly consume cannabis.

NCT ID: NCT02283437 Completed - Family Caregivers Clinical Trials

A Problem-solving Based Bibliotherapy Program for Family Caregivers in Schizophrenia

PSBPF
Start date: April 1, 2018
Phase: N/A
Study type: Interventional

This proposed randomized controlled trial will test the effectiveness of a problem-solving based bibliotherapy program (PSBPF) for Chinese family caregivers in schizophrenia spectrum disorders. A repeated-measures, three-group design will be used to evaluate and compare the effects between two treatment groups (PSBPF and behavioral management group) and routine outpatient service (control group) for 150 randomly selected family caregivers of outpatients with schizophrenia-spectrum disorders over a 18-month follow-up.